Abstract

The Millennium Development Goal 5, a project signed in 2000, intended to improve maternal health and reduce maternal mortality by 75% by 2015. Despite all efforts, little progress has been achieved in low and middle-income countries (LMIC) and 99% of all maternal deaths related to pre-eclampsia (PE) still occur in these settings. It is important to determine whether women in LMIC, where PE carries a greater risk than in high-income countries (HIC), have unique risk factors. Some variances may alter the risk, severity and pertinent pathophysiology of PE. We posit based upon this, that women from LMIC may have biomarkers specific to this population. Discovering such specific biomarkers and testing the relevance of biomarkers developed in high-income populations could increase the clinical usefulness of these analyses without increasing cost-effective approaches for prediction of PE. Here we briefly describe our platform to develop the PREPARE - Biobank in tertiary hospitals or basic units for antenatal care from 6 different cities in Brazil. The PREPARE - Biobank has been developed with two arms. The first arm is a cross-sectional study that will collect clinical information and biosamples from more than 1000 women who developed preterm PE. The second arm is a cohort study of 7000 women. It will collect clinical information and longitudinal biosamples from women at three times during pregnancy, <16 weeks, between 28 and 32 weeks and at delivery or diagnosis of adverse outcomes. The biobank will be supported and complemented by a Brazilian database using the CoLab COLLECT Database.

Highlights

  • Data from the World Health Organization (WHO) show that every day, 830 women die from preventable causes related to pregnancy and childbirth, with the vast majority of these deaths (99%) occurring in low and middle-income countries

  • Among the 133 million babies born alive each year, 2.8 million die in the first week of life. The patterns of these deaths are similar to the patterns for maternal deaths, the majority occurring in developing countries [1]. This sad reality motivated the creation of the Millennium Development Goal 5 (MDG 5), a project signed in 2000 to improve maternal health and reduce maternal mortality by 75% by 2015

  • Purpose of the PREPARE database and biobank Our purpose is to evaluate women with PE and other adverse pregnancy outcomes using data and materials from this PREPARE database and biobank, searching for unique biological biomarkers and testing biomarkers developed in high-income countries (HIC) in the Brazilian population

Read more

Summary

Introduction

Data from the World Health Organization (WHO) show that every day, 830 women die from preventable causes related to pregnancy and childbirth, with the vast majority of these deaths (99%) occurring in low and middle-income countries. The Global Pregnancy Collaboration (CoLab), a group of international researchers from more than 40 countries believes that the creation of a robust biobank linked to a reliable databank is one of the most powerful initiatives, to rapidly and economically, achieve the goal of understanding potential unique features of diseases in the local population. This will empower LMICs to achieve the goal of MDG 5. The PREPARE – Biobank will provide a unique opportunity to bank biological materials from Brazilian women, different from HIC, for present and future mechanistic studies

Purpose of the PREPARE database and biobank
The PREPARE – database
Findings
The PREPARE – biobank
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.